Company highlights Letybo®, presents clinic research and engages with industry leaders through scientific data, brand activations and executive events
IRVINE, Calif., Nov. 18, 2026 /PRNewswire/ -- Hugel Aesthetics, a global leader in medical aesthetics, reinforced its expanding U.S. footprint at the 2026 American Society for Dermatologic Surgery (ASDS) Annual Meeting. Held Nov. 5–8 in San Diego, the meeting brought together leading physicians, researchers and industry stakeholders shaping the future of aesthetic medicine.
As a partner of the ASDS Industry Advisory Council (IAC), Hugel collaborates with the organization to support research and advancement in dermatologic surgery. Throughout the meeting, Hugel's commercial, medical affairs and executive leadership teams engaged with industry leaders through strategic stakeholder discussions, podcast interviews and a company-hosted reception.
The company's presence at the meeting reflects its broader commitment to advancing evidence-based innovation and expanding awareness of K-Aesthetics among U.S. providers and patients. Beyond the convention floor, Hugel further amplified its visibility through on-site scientific data presentations highlighting clinical evidence supporting Letybo (letibotulinumtoxinA-wlbg) and a branded mobile activation showcasing Letybo and K-Aesthetics.
"ASDS brings together some of the most influential voices in dermatology and aesthetics, making it an important forum for scientific collaboration and innovation," said Carrie Strom, CEO of Hugel Aesthetics. "As we continue to expand our presence in the United States, we are proud to partner with the ASDS so that we can contribute meaningful clinical research that helps providers make informed treatment decisions and deliver positive patient outcomes."
Clinical Data Featured at ASDS
Analyses from the BLESS clinical program, authored by board-certified dermatologist and dermatologic surgeon Michael H. Gold, MD, further reinforced the efficacy behind Letybo, speed of onset and patient satisfaction.
Results from the Phase 3 Bless III study1 showed that 64.7% of patients treated with Letybo achieved the study's primary measure for improvement at four weeks, compared with 0% receiving placebo. Patients experienced a median time to improvement of three days, and no serious treatment-related adverse events were reported.
Among women ages 35 to 50, post hoc analyses2 demonstrated rapid and sustained results, with up to 87.4% achieving improvement by week two and 73.6% showing no visible frown lines at maximum frown (GLS 0 on the Glabellar Line Scale) by week four.
A pooled analysis3 of 1,272 participants across three BLESS trials also demonstrated meaningful improvements in quality of life, emotional well-being and treatment satisfaction compared to placebo.
The findings contribute to the growing body of evidence supporting Letybo and underscore Hugel Aesthetics' commitment to advancing research that informs patient care and provider decision making.
About Hugel Aesthetics
Established in 2001, Hugel is a global leader in medical aesthetics, specializing in the production of injectables for skin rejuvenation, including botulinum toxin, hyaluronic acid fillers, and skin boosters, as well as absorbable sutures and cosmetic products. With a proven track record of safety and quality, Hugel is deeply committed to advancing the industry through robust medical affairs, comprehensive training programs and dynamic industry forums.
Over the past 25 years, the company has built a presence in more than 70 countries and operates 11 global subsidiaries across the U.S., Australia, Canada, Taiwan, China, Hong Kong, Singapore and Thailand. Leveraging strong industry momentum, Hugel is well-positioned for continued growth and market expansion worldwide.
Indication
LETYBO® is a prescription medicine for adults that is injected into muscles to temporarily improve the look of moderate to severe frown lines between the eyebrows (glabellar lines).
Important Safety Information
LETYBO® may cause serious side effects that can be life threatening. Call your healthcare provider or get medical help right away if you have any of these problems after treatment with LETYBO®:
- Problems swallowing, speaking, or breathing, due to weakening of associated muscles can be severe and result in loss of life. You are at the highest risk if these problems are pre-existing before injection. Swallowing problems may last for several months.
- Spread of toxin effects. The effect of botulinum toxin may affect areas away from the injection site and cause serious symptoms that include loss of strength and all-over muscle weakness, double vision, blurred vision and drooping eyelids, hoarseness or change or loss of voice, trouble saying words clearly, loss of bladder control, trouble breathing, and trouble swallowing.
Do not receive LETYBO® if you are allergic to any of the ingredients in LETYBO® (see Medication Guide for ingredients); had an allergic reaction to any other botulinum toxin product such as MYOBLOC® (rimabotulinumtoxinB), BOTOX®/BOTOX® COSMETIC (onabotulinumtoxinA), DYSPORT® (abobotulinumtoxinA), XEOMIN® (incobotulinumtoxinA), JEUVEAU® (prabotulinumtoxinA-xvfs), or DAXXIFY® (daxibotulinumtoxinA-lanm); or have a skin infection at the planned injection site.
LETYBO® dosing units are not the same as, or comparable to, any other botulinum toxin product.
Tell your healthcare provider about all your medical conditions, including side effects from botulinum toxin products, including dry eye; breathing, swallowing, bleeding, or heart problems; plans to have surgery; weakness of forehead muscles, drooping eyelids; have had surgery on your face; are pregnant or breastfeeding or plan to become pregnant or breastfeed.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Using LETYBO® with certain other medicines may cause serious side effects. Do not start any new medicines until you have told your healthcare provider that you have received LETYBO® in the past.
Especially tell your healthcare provider if you have received any other botulinum toxin product in the last 4 months or any in the past, and exactly which product you received (such as MYOBLOC®, BOTOX®/BOTOX® COSMETIC, DYSPORT®, XEOMIN®, JEUVEAU®, or DAXXIFY®). LETYBO® may cause serious side effects, including allergic reactions (such as itching, rash, hives, wheezing, trouble breathing, or dizziness or feeling faint), heart problems (such as irregular heartbeat and heart attack), and eye problems (including dry eye, reduced blinking, and corneal problems). Tell your healthcare provider or get help right away if you experience a serious side effect. No serious side events of distant spread of toxin effect associated with dermatologic use of LETYBO® have been reported in clinical studies at the dose of 20 Units for glabellar lines. The most common side effect of LETYBO® was headache.
These are not all the possible side effects of LETYBO®. For more information, see the full Prescribing Information including Boxed Warning, and refer to the Medication Guide or talk with your doctor. To report side effects associated with LETYBO®, please call 1-877-390-2906. You may also report side effects to the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch.
_______________________ |
US-LETI-2600122 11/26
SOURCE Hugel


Share this article